U.S. Marine and Shipping Stock News

Anyone interested in FB Financial Corporation ( NYSE:FBK ) should probably be aware that the Chief Accounting Officer...

We can readily understand why investors are attracted to unprofitable companies. By way of example, Camp4 Therapeutics...

RenaissanceRe Holdings stock has delivered a 124.7% return over the past 5 years, and the current valuation checks indicate that the shares may still be inexpensive relative to the company’s fundamentals. RenaissanceRe Holdings' 124.7% 5-year return indicates that long-term holders have already seen solid gains, so any further upside may depend on whether current expectations for the business remain intact. For a reinsurer like RenaissanceRe Holdings, the outlook for underwriting...

We wouldn't blame Incyte Corporation ( NASDAQ:INCY ) shareholders if they were a little worried about the fact that...

Viewing insider transactions for Candel Therapeutics, Inc.'s ( NASDAQ:CADL ) over the last year, we see that insiders...

The new 25% US tariff on a broad range of Brazilian imports puts fresh attention on US Domestic Manufacturing stocks that could see shifts in demand, costs, or competitive positioning as supply chains adjust. With key Brazilian exports like coffee, beef, orange juice, and aircraft parts exempt, the impact is focused on other areas where domestic producers might gain or face new pressures. This article walks through 3 stocks from the US Domestic Manufacturing screener that appear positively...

Looking at Anteris Technologies Global Corp.'s ( NASDAQ:AVR ) insider transactions over the last year, we can see that...

Some Tower Semiconductor Ltd. ( NASDAQ:TSEM ) shareholders may be a little concerned to see that the CEO & Director...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Immunome (IMNM) is in focus after the FDA accepted its New Drug Application for varegacestat, an oral therapy for adults with desmoid tumors, supported by positive Phase 3 RINGSIDE trial data. See our latest analysis for Immunome. The FDA’s acceptance of Immunome’s NDA comes after a mixed period for the stock, with a 20.45% 1 month share price return but a 9.38% decline over three months. The 1 year total shareholder return of 110.96% points to strong longer term momentum. If this kind of...

UroGen Pharma (URGN) is back in focus after the FDA cleared its Investigational New Drug application for UGN-501, allowing the company to move ahead with a Phase 1 bladder cancer study. See our latest analysis for UroGen Pharma. Against this backdrop, UroGen Pharma’s share price has climbed strongly, with a 30-day share price return of 22.62% and a 90-day share price return of 78.48%, while the 1-year total shareholder return of 163.46% points to powerful momentum rather than a short-lived...

Halliburton (NYSE:HAL) has secured multi-year contracts from Saudi Aramco covering unconventional gas development and onshore oil activities. The work includes deployment of Saudi Arabia’s first intelligent fracturing platform as part of a major unconventional gas project. The agreements also span a multi-year integrated oilfield program across hundreds of planned wells. Halliburton will expand local manufacturing and workforce commitments to support these projects. For investors watching...

Cousins Properties (CUZ) has drawn fresh attention after recent trading, with the stock closing at $31.76 and showing double digit gains over both the past month and the past three months. See our latest analysis for Cousins Properties. The recent share price move in Cousins Properties builds on stronger momentum, with a 30 day share price return of 14.62% and a 90 day share price return of 31.84%, alongside a 1 year total shareholder return of 18.07%. If recent gains in Cousins Properties...

ANI Pharmaceuticals has delivered a strong 139.1% return over the past 5 years, yet at around US$79.20 the valuation checks now suggest the stock is closer to fairly priced than obviously cheap. A 139.1% total return over 5 years indicates ANI Pharmaceuticals has already rewarded patient shareholders, so fresh buyers may be weighing how much of the story is reflected in the current price. Positive topline data from the SYNCHRONICITY trial can support expectations for the branded portfolio,...

Bell Canada has completed its first direct to device satellite ground station to support AST SpaceMobile's network in Canada. AST SpaceMobile secured new regulatory approval in New Zealand, expanding its potential service footprint. The company is preparing for the launch of additional BlueBird satellites to build out its direct to device constellation. AST SpaceMobile (NasdaqGS:ASTS) is back in focus as it adds fresh infrastructure and regulatory pieces to its direct to device puzzle. The...

Geopolitics just moved back to the front of the market’s attention, with U.S. strikes on Iran, drone and missile attacks across the Gulf, and oil prices reacting sharply. When tensions spill into shipping lanes and supply chains, some stocks can gain new contracts or attention, while others face higher risks and costs. This article looks at how that mix of risk and opportunity connects to the latest Defense and Aerospace Stocks screener and highlights 3 stocks that appear positively exposed...

Abbott Laboratories (ABT) just posted Q2 2026 revenue of about US$12.6b with basic EPS of US$0.53, alongside trailing twelve month revenue of roughly US$46.6b and EPS of US$3.11. Over recent quarters the company has seen revenue move from about US$11.1b in Q2 2025 to US$12.6b in Q2 2026, while quarterly EPS shifted from US$1.02 to US$0.53. This sets up a results season where investors are likely to focus closely on how margins are holding up in the current mix of growth drivers. See our full...

Oscar Health (OSCR) is back in focus after recent analyst reports cited substantial upward revisions in earnings estimates and a top Zacks Rank #1 rating, prompting fresh attention from both value and momentum investors. See our latest analysis for Oscar Health. The recent attention on Oscar Health has come alongside a sharp swing in momentum, with a 1-day share price return of 0.83% and a 7-day share price return down 4.72%, set against a 90-day share price return of 84.29% and a 1-year...

EchoStar CEO Hamid Akhavan has resigned, with leadership duties moving to Charles W. Ergen and Thomas A. Cullen. The change comes alongside a shift in EchoStar's strategic direction affecting how key business units are run. Investors are assessing what the new leadership structure could mean for culture, execution, and the company’s future focus. EchoStar, traded as NasdaqGS:ECHO, is entering a transition period at a time when its share price sits at $92.0. The stock is down 4.2% over the...

Intuitive Surgical (ISRG) has released its Q2 2026 numbers, with revenue of US$2.9 billion and basic EPS of US$2.31, set against trailing 12 month revenue of US$11.0 billion and EPS of US$8.84. Over recent quarters, the company has seen revenue move from US$2.44 billion in Q2 2025 to US$2.89 billion in Q2 2026, while quarterly EPS shifted from US$1.84 to US$2.31, with trailing earnings up 20.4% over the past year and 16.7% per year over the past five years. With a net profit margin of 28.4%...

Federal Agricultural Mortgage stock has delivered strong long term gains for shareholders over the past five years, yet the latest valuation work suggests the current share price may still sit below an intrinsic value estimate based on the Excess Returns model. At the same time, traditional earnings multiples look roughly in line with peers, which raises the question of whether the recent share price level around US$205.50 already reflects most of the good news. Federal Agricultural Mortgage...

Arrow Electronics has surged 82.8% year to date. After that kind of run, the key issue for investors is whether the stock’s current valuation still leaves a reasonable margin of safety or is starting to price in a lot of good news upfront. The 82.8% gain year to date suggests expectations around Arrow Electronics have shifted sharply higher, and the stock is now priced for continued delivery rather than a simple recovery story. Recent AI driven growth in components for data centers and...

Primoris Services has delivered a strong 210.3% total return over the past five years, yet its current valuation screens as cheap, with both a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples suggesting the stock trades at a discount to what the business may be worth. Over five years, Primoris Services has returned 210.3%, which puts recent share price weakness in the context of a strong longer term run. Recent coverage highlighting revenue growth, backlog expansion...

Freedom Holding Corp. recently completed a US$300,000,000 follow-on equity offering under Regulation S, issuing 2,374,356 common shares at US$126.35005 each, and also announced the resignation of board member Kairat Kelimbetov, effective July 8, 2026. The combination of a sizable capital raise and a reduction in board size highlights an important moment for how Freedom Holding balances governance and growth-oriented funding decisions. We will now examine how the US$300,000,000 follow-on...